-

05:26:55 AM

CMMB Stock News

CMMB - Chemomab Therapeutics Ltd

11/30/22 7:00 AM

Nasdaq : CMMB

managementlow float

Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the

RHEA-AI

very positive

11/11/22 6:00 AM

Nasdaq : CMMB

earningslow float

Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic

RHEA-AI

neutral

11/09/22 8:00 AM

Nasdaq : CMMB

clinical trialcovid-19low float

Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery

RHEA-AI

neutral

11/01/22 7:00 AM

Nasdaq : CMMB

conferencesearningslow float

Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company

RHEA-AI

neutral

10/28/22 7:00 AM

Nasdaq : CMMB

conferenceslow float

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company

RHEA-AI

neutral

08/12/22 6:00 AM

Nasdaq : CMMB

low float

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the

RHEA-AI

very positive

08/12/22 6:00 AM

Nasdaq : CMMB

earningslow float

Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for

RHEA-AI

neutral

08/01/22 7:00 AM

Nasdaq : CMMB

conferencesearningslow float

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company

RHEA-AI

neutral

06/27/22 8:00 AM

Nasdaq : CMMB

low float

Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the

RHEA-AI

neutral

06/21/22 7:00 AM

Nasdaq : CMMB

managementlow float

Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on

RHEA-AI

very positive

CMMB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.chemomab.com
Security nameChemomab Therapeutics Ltd - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2021

About Chemomab Therapeutics Ltd

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022.